Maria Cruse
Psychiatry · Thibodaux, LANPI 1538197025
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $497,225 of the $522,273 with a category attached, or 95.2%. AbbVie accounts for 100.0% of it on its own, with 4 other manufacturers making up the rest. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 647 payments — averaging $807.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$522K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$138
- Takeda Pharmaceuticals U.S.A., Inc.$58
- Sunovion Pharmaceuticals Inc.$23
- Ironwood Pharmaceuticals, Inc$15
What the payments were for
- Speaking & faculty fees$497,22595%
- Travel & lodging$19,2024%
- Food & beverage$5,8461%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 640 | $522,038 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$522,273 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 41 | $72,640 |
| Vilazodone Hcl | 62 | $6,204 |
| Duloxetine Hcl | 450 | $5,101 |
| Lamotrigine | 234 | $3,621 |
| Bupropion XlBupropion Hcl | 157 | $3,209 |
| Quetiapine Fumarate | 191 | $3,042 |
| Aripiprazole | 94 | $2,210 |
| Mirtazapine | 170 | $1,992 |
| Memantine Hcl ErMemantine Hcl | 32 | $1,924 |
| Buspirone Hcl | 80 | $1,765 |
| Clonazepam | 160 | $1,294 |
| Trazodone Hcl | 143 | $967 |
| Olanzapine | 84 | $946 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 17 | $870 |
| Fluoxetine Hcl | 56 | $821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $522,038 | $72,64041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Thibodaux
- Patrick HayesLake Charles$837K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
- Jasjit SinghShreveport$420K
- Roger BrownMandeville$216K
- Abdul KhanBaton Rouge$156K
- William ColombMandeville$117K
- Andrew MorsonNew Orleans$56K
- Frank WeinholtWest Monroe$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.